C73 Insurance Policy Changes

ICD-10 C73 is officially defined as "Malignant neoplasm of thyroid gland." code C73 is referenced in 26 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Excellus BlueCross BlueShield, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C73 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of North Dakota · Effective Dec 10, 2026Medium impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota's pharmacy policy notice dated October 15, 2026 lists revisions to commercial prior authorization medical drug policies effective December 10, 2026, including Adzynma, Amtagvi, Benlysta IV, Berinert, Cinryze, Emrelis, Injectafer, Lutetium dotatate, Rituximab IV, Tecentriq IV, Tevimbra and Ziihera. Revisions to commercial post service claim edit medical drug policies, including Torisel and Xofigo, were effective November 1, 2026. Many of the entries update the contractor name to Wellpoint Federal and add the number of days allowed for authorization durations.
Blue Cross Blue Shield of North Dakota · Identified Aug 29, 2026High impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota revised its Commercial prior authorization medical drug policies with changes effective October 13, 2026, including expanded indications for Casgevy, Keytruda, Opdivo and other products and updated criteria for many others. Effective September 1, 2026, Navitrux was added to the fosaprepitant policy and Cligavyx was added to the fulvestrant policy, each kept at full parity with its reference product, and the cerebral palsy spasticity exclusion was removed from the Xeomin pediatric upper limb indication. Several products also have HCPCS code changes effective January 1, 2027.
Excellus BlueCross BlueShield · Effective Apr 16, 2026Medium impact
Germline Genetic Testing for Hereditary Cancers 2.02.60
Excellus BlueCross BlueShield policy 2.02.60 considers germline genetic testing for hereditary cancer medically appropriate in listed circumstances, including when a blood relative has a known pathogenic or likely pathogenic variant, when a pathogenic or likely pathogenic variant is found on tumor genomic testing, when results aid systemic therapy or surgical decisions, and when individuals meet specific criteria for breast, ovarian, pancreatic, prostate, colorectal, Cowden syndrome, Li-Fraumeni syndrome, hereditary diffuse gastric cancer or familial medullary thyroid carcinoma. Multigene panel testing is considered medically appropriate when an individual meets Policy Statement I, except Policy Statements I.A, I.D and I.G.9. The current effective date is April 16, 2026, and the annual update kept the policy intent unchanged.
Excellus BlueCross BlueShield · Effective Nov 20, 2025Medium impact
Molecular Marker Testing of the Thyroid 2.02.49
Afirma Genomic Sequencing Classifier and ThyroSeq are considered medically necessary when indeterminate cytology (Bethesda category III or IV) is present, there are no strong clinical or radiologic findings suggestive of malignancy, and surgical decision making would be affected by the results. ThyroSeq, ThyraMIR microRNA/ThyGenX, Afirma BRAF and Afirma MTC are also considered medically necessary for Bethesda category III, IV or V cytology when malignancy must be determined and the results guide surgical planning for initial resection. RosettaGX Reveal, single-gene TERT testing, Thyroid GuidePx and Afirma Xpression Atlas are considered investigational. The 11/20/25 annual review made no changes to policy intent, although the policy statements were reformatted for clarity.
Aetna · Identified Nov 4, 2026Medium impact
Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag) (CPB 0892, reviewed 2026-10-28)
Aetna's clinical policy bulletin CPB 0892, last reviewed 2026-10-28, sets the coverage criteria for nivolumab (Opdivo), nivolumab and hyaluronidase-nvhy (Opdivo Qvantig), and nivolumab and relatlimab-rmbw (Opdualag) for Aetna commercial medical plans, including indication-by-indication initial approval criteria, continuation-of-therapy criteria, and dosing references. Precertification is required for all three products, and the site-of-care utilization management policy applies. The practice's billing team should align charge entry, precertification tracking, and documentation with the indications and continuation limits listed for each product.
Aetna · Identified Oct 22, 2026Medium impact
Intraoperative Radiation Therapy (IORT) (CPB 0721, reviewed 2026-10-15)
Aetna Clinical Policy Bulletin 0721 sets Aetna's coverage rules for intraoperative radiation therapy (IORT). Aetna considers IORT medically necessary for cervical cancer, colorectal cancer, soft tissue sarcoma (including retroperitoneal sarcoma) and uterine cancer, and considers single-fraction electron-beam IORT at the time of lumpectomy medically necessary for breast cancer when the selection criteria are met. Aetna considers IORT experimental, investigational or unproven for brain tumors and brain metastasis, cholangiocarcinoma, conjunctival neoplasms, gastric cancer, glioma, head and neck cancers, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, spinal and vertebral metastases, sporadic renal angiomyolipoma and thymoma, and notes that this list is not all-inclusive.
Aetna · Identified Oct 10, 2026Medium impact
Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-10-05)
Aetna considers radiofrequency ablation (RFA) medically necessary for indications that include colorectal cancer liver metastases, colorectal cancer lung metastases of 5 cm or less where the primary colorectal tumor has been resected for cure (R0 resection), malignant lung masses in persons who are not candidates for surgical intervention, solitary hepatocellular carcinoma of 5 cm or less or multinodular early-stage HCC in members who are ineligible for or decline surgical resection or transplantation, renal cell carcinoma up to 4 cm in high-risk surgical candidates or in persons with renal insufficiency or a solitary kidney, and osteoid osteoma in individuals who remain symptomatic despite NSAIDs. Aetna considers RFA experimental, investigational, or unproven for combined RFA with transarterial chemoembolization for intermediate-stage hepatocellular carcinoma, combined endoluminal RFA and stenting for malignant biliary obstruction or stricture, combined RFA and vertebral cement augmentation for spinal metastases, endoscopic ultrasound-guided RFA for aldosterone-producing adenomas, and all other indications, including curative treatment of primary or metastatic malignant neoplasms in persons able to tolerate surgical resection, biliary obstructions or strictures, renal cysts, renal angiomyolipomas, Brunner's gland hyperplasia, and unresectable localized recurrent thyroid cancers without distant metastases.
Aetna · Identified Oct 8, 2026Medium impact
Docetaxel (CPB 0956, reviewed 2026-10-05)
For commercial medical plans, docetaxel (Beizray, Docivyx, Taxotere, or generic docetaxel) is considered medically necessary for the listed cancer indications, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer, ovarian cancer, small cell lung cancer, and soft tissue sarcoma. Breast cancer requires the disease-status criteria stated in the policy, and continuation of therapy is considered medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen. All other indications are considered experimental, investigational, or unproven.
Aetna · Identified Sep 30, 2026Medium impact
Denosumab (CPB 0804, reviewed 2026-08-21)
Aetna covers Prolia and its ten listed biosimilars, and Xgeva and its nine listed biosimilars, under commercial medical plans, and precertification is required for these denosumab products in applicable plan designs. Prolia is considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and inhibiting progression of bone erosion in rheumatoid arthritis, based on criteria such as fragility fracture history, pre-treatment T-score, pre-treatment FRAX probability, and prior therapy response or intolerance. Xgeva is considered medically necessary for multiple myeloma, bone metastases from solid tumors, giant cell tumor of bone, hypercalcemia of malignancy refractory to intravenous bisphosphonate therapy, and second-line therapy for osteopenia or osteoporosis in systemic mastocytosis, and continuation of Xgeva requires disease stability or improvement.
Aetna · Identified Aug 19, 2026Medium impact
Intraoperative Radiation Therapy (IORT) (CPB 0721, reviewed 2025-10-20)
Aetna considers intraoperative radiation therapy (IORT) medically necessary for cervical cancer, colorectal cancer, soft tissue sarcoma (including retroperitoneal sarcoma), and uterine cancer, and considers single-fraction electron-beam IORT at the time of lumpectomy medically necessary for breast cancer when the selection criteria are met. For breast cancer, the criteria are a documented diagnosis of early stage (0, I or II) breast cancer, negative lymph nodes, technically clear surgical margins, and a tumor less than or equal to 5 cm in diameter. IORT is considered experimental, investigational, or unproven for brain tumors and brain metastasis, cholangiocarcinoma, conjunctival neoplasms, gastric cancer, glioma, head and neck cancers, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, spinal metastases, sporadic renal angiomyolipoma, thymoma, and vertebral metastases (the list is not all-inclusive).
Aetna · Identified Aug 18, 2026Medium impact
Thyrogen (Thyrotropin Alfa) (CPB 0515, reviewed 2026-08-05)
Aetna's Clinical Policy Bulletin 0515 covers Thyrogen (thyrotropin alfa) for commercial medical plans as medically necessary for three uses: as an adjunctive diagnostic tool for thyroglobulin testing with or without radioiodine imaging in follow-up of well-differentiated thyroid carcinoma after thyroidectomy, as an adjunct to radioiodine ablation of thyroid remnants after near-total or total thyroidectomy for well-differentiated thyroid cancer, and as an adjunct to radioiodine ablation therapy for non-toxic multi-nodular goiter. The recommended regimen is two 0.9 mg intramuscular injections, the second given 24 hours after the first. Aetna considers thyrotropin alfa experimental, investigational, or unproven for all other indications, such as differentiated thyroid cancer with suppressed serum thyroglobulin below 0.1 ng/ml.
Aetna · Identified Aug 18, 2026Medium impact
Temsirolimus (Torisel) (CPB 0873, reviewed 2025-10-09)
Aetna considers temsirolimus (Torisel or generic temsirolimus) medically necessary as a single agent for subsequent treatment of locally advanced, recurrent, or metastatic endometrial carcinoma, for relapsed or refractory mantle cell lymphoma, and for advanced renal cell carcinoma. It also considers it medically necessary for specified soft tissue sarcoma subtypes, for rhabdomyosarcoma (maximum 12 cycles, with cyclophosphamide and vinorelbine), and for subsequent treatment of advanced, recurrent/metastatic, or inoperable PEComa in uterine sarcoma. Aetna considers all other indications experimental, investigational, or unproven, and considers continuation of therapy medically necessary when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Solid Tumors in Adults (CPB 0811, reviewed 2025-12-03)
Aetna's Clinical Policy Bulletin 0811 considers autologous or allogeneic hematopoietic stem cell transplant, both ablative and non-myeloablative, experimental, investigational, or unproven for the following adult solid tumors: bile duct (cholangiocarcinoma), breast, central nervous system tumors, cervix, colon, esophagus, fallopian tube, gallbladder, kidney, liver, lung, melanoma, nasopharynx, neuroendocrine tumors, pancreas, paranasal sinus, prostate, rectum, soft tissue sarcomas, stomach, thymus, thyroid, tumors of unknown primary origin, and uterus. Aetna considers autologous hematopoietic stem cell transplant medically necessary in young adults with primitive neuroectodermal tumors, medulloblastoma, and Ewing sarcoma family of tumors when criteria are met in CPB 0496.
Aetna · Identified Aug 16, 2026Medium impact
Lutetium Lu 177 Dotatate (Lutathera) and Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) (CPB 0929, reviewed 2026-07-17)
Aetna's policy covers lutetium Lu 177 dotatate (Lutathera) and lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for commercial medical plans. Lutathera is medically necessary for four doses total for specified somatostatin receptor-positive neuroendocrine tumors, poorly controlled carcinoid syndrome, and pheochromocytoma/paraganglioma when the listed criteria are met, and Pluvicto is medically necessary for up to 6 total doses lifetime for PSMA-positive metastatic castration-resistant prostate cancer when all listed criteria are met. Aetna considers both drugs experimental, investigational, or unproven for all other indications, including Lutathera for medullary thyroid carcinoma and meningioma.
Aetna · Identified Aug 16, 2026Medium impact
Ribavirin for Inhalation Use (CPB 0155, reviewed 2026-04-21)
Aetna considers ribavirin for inhalation medically necessary for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Aetna considers all other indications experimental, investigational, or unproven, including the cationic liposome encapsulated ribavirin spray for the treatment of acute pneumonia. Ribavirin for inhalation is not indicated for use in adults.
Aetna · Identified Aug 16, 2026Medium impact
RET Proto-Oncogene Testing (CPB 0319, reviewed 2026-06-08)
Aetna considers germline RET proto-oncogene testing medically necessary for members with a personal history of medullary thyroid carcinoma (familial or apparently sporadic), pheochromocytoma or paraganglioma when multiple endocrine neoplasia type 2 (MEN2) is suspected, parathyroid adenoma or hyperplasia when MEN2A is suspected, C-cell hyperplasia on pathology, or clinical features of MEN2B. Family history criteria include a first-degree blood relative with medullary thyroid carcinoma, a first-degree or second-degree blood relative with a known germline RET pathogenic variant, and a family pattern consistent with familial medullary thyroid carcinoma. Germline RET testing for all other indications, such as non-small cell lung cancer, is considered experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-07-29)
Aetna considers radiofrequency ablation (RFA) medically necessary for several tumor indications, including colorectal cancer liver metastases, colorectal lung metastases of 5 cm or less where the primary colorectal tumor has been resected for cure (R0 resection), and malignant lung masses in persons who are not candidates for surgical intervention. Solitary hepatocellular carcinoma of 5 cm or less is covered in members who are ineligible for or decline surgical resection or transplantation, and renal cell carcinoma up to 4 cm is covered in high-risk surgical candidates, persons with renal insufficiency, or persons with a solitary kidney. The policy lists curative RFA of malignant neoplasms in persons who are able to tolerate surgical resection, combined RFA with trans-arterial chemoembolization for intermediate-stage hepatocellular carcinoma, combined endoluminal RFA and stenting for malignant biliary obstruction or stricture, and combined RFA with vertebral cement augmentation for spinal metastases as experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Ethanol Injection for Thyroid Lesions and Other Selected Indications (CPB 0395, reviewed 2026-07-06)
Ethanol sclerotherapy of thyroglossal duct cysts is medically necessary only when a monocystic lesion is present, cystographic studies show no extravasation, and cytology shows the lesion is benign. Ethanol sclerotherapy is also medically necessary for symptomatic venous malformations of the head and neck, absolute ethanol injection is medically necessary for overt upper gastrointestinal bleeding, and ethanol ablation is medically necessary for benign thyroid nodules. Ethanol sclerotherapy for endometrioma, intradiscal radiopaque gelified ethanol injection for lumbar disc herniation, percutaneous ethanol injection for thyroid cancer, and ultrasound-guided ethanol sclerotherapy for Warthin's tumor are considered experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Pemetrexed Products (CPB 0687, reviewed 2026-07-17)
Aetna considers pemetrexed (Alimta, Axtle, Pemfexy, Pemrydi RTU, or generic pemetrexed) medically necessary for commercial members with the listed indications: non-squamous non-small cell lung cancer, pleural and peritoneal mesothelioma, ovarian, fallopian tube and primary peritoneal cancer, cervical cancer, bladder cancer, primary CNS lymphoma, thymoma and thymic carcinoma, thyroid cancer, and vaginal cancer. Members with squamous cell non-small cell lung cancer are not eligible, and indications such as breast, colorectal, gastric, pancreatic and small cell lung cancer are experimental, investigational, or unproven. Continuation is covered when there is no unacceptable toxicity or disease progression, and use with pembrolizumab for pleural or peritoneal mesothelioma is covered for up to 24 months total.
Aetna · Identified Aug 13, 2026Medium impact
Docetaxel (CPB 0956, reviewed 2025-12-04)
Aetna considers docetaxel (Beizray, Docivyx, Taxotere or generic docetaxel) medically necessary for the cancers listed in the policy, including breast cancer, non-small cell lung cancer, prostate cancer, gastric and esophageal cancers, head and neck cancer, bladder cancer, soft tissue sarcoma, uterine neoplasms and others, and considers continuation medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen. Aetna considers all other indications experimental, investigational or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Dostarlimab-gxly (Jemperli) (CPB 0993, reviewed 2026-01-27)
For commercial medical plan members, Aetna considers dostarlimab-gxly (Jemperli) medically necessary under its initial approval criteria for several mismatch repair deficient or microsatellite instability-high cancers, including endometrial, ampullary, breast, colorectal, esophageal, gastric, ovarian, pancreatic, small bowel and anal cancers. It also considers Jemperli in combination with pemetrexed and platinum chemotherapy for first-line metastatic nonsquamous non-small cell lung cancer without genomic aberrations. Members are not eligible when they have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy, and all other indications are considered experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Denosumab (CPB 0804, reviewed 2026-06-08)
Aetna's commercial medical policy sets coverage criteria for Prolia and its biosimilars and for Xgeva and its biosimilars, and precertification is required for these products in applicable plan designs. Prolia and its biosimilars are considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer, and inhibiting progression of bone erosion in rheumatoid arthritis. Xgeva and its biosimilars are considered medically necessary for multiple myeloma, bone metastases from a solid tumor, giant cell tumor of bone, hypercalcemia of malignancy refractory to intravenous bisphosphonate therapy, and second-line therapy for osteopenia or osteoporosis in systemic mastocytosis. All other indications are considered experimental, investigational, or unproven, and combination therapy of denosumab with intravenous bisphosphonates is also considered experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Paclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)
Aetna considers albumin-bound paclitaxel (Abraxane or generic albumin-bound paclitaxel) medically necessary for the cancers listed in its initial approval criteria, including Kaposi sarcoma, breast cancer, cutaneous melanoma, endometrial carcinoma, ovarian, fallopian tube and primary peritoneal cancer, biliary tract cancers, non-small cell lung cancer, pancreatic adenocarcinoma, small bowel adenocarcinoma, uveal melanoma, ampullary adenocarcinoma, cervical cancer, bladder cancer and vaginal cancer, when each cancer's stated criteria are met. All other indications are considered experimental, investigational, or unproven, including small cell lung cancer, prostate cancer, soft-tissue sarcoma and gastric cancer. Continuation of therapy is medically necessary for an approved indication when there is no evidence of unacceptable toxicity or disease progression on the current regimen.
Aetna · Identified Aug 12, 2026Medium impact
Optical Coherence Tomography and Microelastography for Solid Tumors and Other Selected Indications (CPB 0886, reviewed 2026-03-03)
Aetna considers optical coherence tomography and microelastography experimental, investigational, or unproven for the listed intra-operative uses because their effectiveness has not been established. These uses include assessment of lymph nodes or tumor margins in breast conserving surgery, differentiation of pancreatic neoplastic lesions, differentiation of normal and diseased thyroid and parathyroid tissues, and solid tumor surgery including optical biopsy of lymph nodes and real-time determination of surgical margins. The policy lists CPT codes and ICD-10 codes as not covered for the indications it names.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Intensity-Modulated Radiotherapy (IMRT): Cancer of the Head and Neck or Thyroid
A 09/15/2025 update changed the description of intensity modulators and radiotherapy treatment planning systems, and the policy statements were unchanged. Intensity-modulated radiotherapy may be considered medically necessary for head and neck cancers, which the policy defines as cancers of the oral cavity and lip, larynx, hypopharynx, oropharynx, nasopharynx, paranasal sinuses and nasal cavity, salivary glands, and occult primaries in the head and neck region. For thyroid cancer, it may be considered medically necessary when the cancer is in close proximity to organs at risk (esophagus, salivary glands, and spinal cord) and 3D conformal radiotherapy planning is not able to meet dose volume constraints for normal tissue tolerance. Intensity-modulated radiotherapy is investigational for thyroid cancers that do not meet these criteria.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Molecular Markers in Fine Needle Aspirates of the Thyroid
For individuals with thyroid nodules without strong clinical or radiologic findings suggestive of malignancy, in whom surgical decision making would be affected by test results, the Afirma Genomic Sequencing Classifier or ThyroSeq may be considered medically necessary on fine needle aspirates with indeterminate cytology (Bethesda category III or IV). Gene expression classifiers, genetic variant analysis, and molecular marker testing that do not meet the policy criteria, including single-gene TERT testing, are considered investigational.

Watch C73

Get one email when a payer policy names C73, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C73?

There are 26 tracked policy changes affecting code C73, including updates from Blue Cross Blue Shield of North Dakota, Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C73?

Payers that have issued tracked updates for code C73 include: Blue Cross Blue Shield of North Dakota, Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code C73 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C73. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C73?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pharmacy Policies Available Online

Pharmacy Policies Available Online

Germline Genetic Testing for Hereditary Cancers 2.02.60

Molecular Marker Testing of the Thyroid 2.02.49

Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag) (CPB 0892, reviewed 2026-10-28)

Intraoperative Radiation Therapy (IORT) (CPB 0721, reviewed 2026-10-15)

Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-10-05)

Docetaxel (CPB 0956, reviewed 2026-10-05)

Denosumab (CPB 0804, reviewed 2026-08-21)

Intraoperative Radiation Therapy (IORT) (CPB 0721, reviewed 2025-10-20)

Thyrogen (Thyrotropin Alfa) (CPB 0515, reviewed 2026-08-05)

Temsirolimus (Torisel) (CPB 0873, reviewed 2025-10-09)

Hematopoietic Cell Transplantation for Solid Tumors in Adults (CPB 0811, reviewed 2025-12-03)

Lutetium Lu 177 Dotatate (Lutathera) and Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) (CPB 0929, reviewed 2026-07-17)

Ribavirin for Inhalation Use (CPB 0155, reviewed 2026-04-21)

RET Proto-Oncogene Testing (CPB 0319, reviewed 2026-06-08)

Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-07-29)

Ethanol Injection for Thyroid Lesions and Other Selected Indications (CPB 0395, reviewed 2026-07-06)

Pemetrexed Products (CPB 0687, reviewed 2026-07-17)

Docetaxel (CPB 0956, reviewed 2025-12-04)

Dostarlimab-gxly (Jemperli) (CPB 0993, reviewed 2026-01-27)

Denosumab (CPB 0804, reviewed 2026-06-08)

Paclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)

Optical Coherence Tomography and Microelastography for Solid Tumors and Other Selected Indications (CPB 0886, reviewed 2026-03-03)

Intensity-Modulated Radiotherapy (IMRT): Cancer of the Head and Neck or Thyroid

Molecular Markers in Fine Needle Aspirates of the Thyroid

What insurance policy changes affect code C73?

Which payers have updated policy for code C73?

How do I get notified when code C73 policy changes?

Why do payers change policies for code C73?